Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

RPL554 Maintains Asthmatics Bronchodilation

By Drug Discovery Trends Editor | August 19, 2011

Verona Pharma completed a Phase 2 study to test the duration of bronchodilator action with repeated doses of its lead drug, RPL554, in patients with mild asthma.

The trial took place at the Center for Human Drug Research (CHDR) and treated 12 patients with mild asthma with daily doses of RPL554 for a period of 6 days. The patients were tested daily but the major observations on bronchodilation were on days 1, 3 and 6 when measurements were continued for 6 hours. The assessment of bronchodilation was based on FEV1 (forced expiratory volume at 1 second), a common method used to evaluate the bronchodilator effects of drugs. The trial was a single blind, randomized, placebo-controlled trial.

The trial demonstrated that RPL554 had sustained bronchodilator actions throughout the treatment period. There was no accumulation of the drug in plasma and no safety issues were observed. There was a minor increase in heart rate at day 6 only, being the last day of treatment.

This is the third trial with RPL554 in patients with allergic asthma. The second trial established the effectiveness of higher doses of the drug. A further trial is being planned to test the anti-inflammatory actions of RPL554 and is expected to start later in 2011.

“The clinical studies performed so far with RPL554 have defined the actions of our drug in terms of doses that are safe and produce a clear and unequivocal bronchodilator effect. This bronchodilator effect is of value in the treatment of asthma, and possibly chronic obstructive pulmonary disease (COPD). The sustained bronchodilator effect of RPL554 throughout the treatment period is an important finding, and one that we will use when selecting the dosing regimen for a further trial we are currently planning to demonstrate unequivocally the anti-inflammatory actions of RPL554,” says Michael Walker, chief executive officer of Verona Pharma.

Release Date: August 17, 2011
Source: Verona Pharma 


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE